Company profile for Mission Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Our vision is to transform the treatment of serious diseases by targeting disease-associated deubiquitylating enzymes to harness a new class of drugs. Understanding the complexity of our goal, we focus on areas of significant unmet medical need – disease areas where new therapeutics have the potential to make dramatic improvements in the quality of life and survival of patients. Mission Therapeutics is determined to make a ...
Our vision is to transform the treatment of serious diseases by targeting disease-associated deubiquitylating enzymes to harness a new class of drugs. Understanding the complexity of our goal, we focus on areas of significant unmet medical need – disease areas where new therapeutics have the potential to make dramatic improvements in the quality of life and survival of patients. Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Granta Park Great Abington Cambridge CB21 6GP United Kingdom
Telephone
Telephone
+44 (0)1223 607 340
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-10-15/mission-therapeutics-raises-133-million-to-progress-first-in-class-parkinson-s-disease-candidate-mtx325-through-clinical-trials

PHARMIWEB
15 Oct 2025

https://www.prnewswire.com/news-releases/mission-therapeutics-announces-publication-in-nature-reviews-drug-discovery-of-article-highlighting-how-neurodegenerative-diseases-can-be-tackled-by-enhancing-mitophagy-302350801.html

PR NEWSWIRE
15 Jan 2025

https://www.prnewswire.com/news-releases/mission-therapeutics-awarded-5-2m-from-the-michael-j-fox-foundation-and-parkinsons-uk-to-advance-potential-disease-modifying-treatment-mtx325--302187338.html

PR NEWSWIRE
02 Jul 2024

https://endpts.com/pfizer-backed-mission-therapeutics-raises-25m-to-advance-mitophagy-pipeline/

Ayisha Sharma ENDPTS
14 Mar 2024

https://www.prnewswire.com/news-releases/mission-therapeutics-announces-us-fda-approval-to-initiate-phase-ii-clinical-trial-of-its-lead-asset-mtx652-in-acute-kidney-injury-302014249.html

PR NEWSWIRE
14 Dec 2023

https://www.prnewswire.com/news-releases/mission-therapeutics-granted-mhra-clinical-trial-authorisation-cta-for-mtx325-for-the-treatment-of-parkinsons-disease-302005510.html

PR NEWSWIRE
05 Dec 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty